Newron Pharmaceuticals - Evenamide efficacy still going strong after 52 weeks
Newron Pharmaceuticals has announced positive interim results from the first 100 randomised patients completing one year of treatment (77 out of 100) in the Phase II 014/015 clinical trial (international, open label, rater-blinded study), in which evenamide is an add-on therapy to antipsychotics in moderate to severe treatment-resistant schizophrenia (TRS). The data are consistent with a gradual and sustained pattern of improvement in key efficacy measures compared with results after six weeks and six months of treatment, with the proportion of patients achieving meaningful improvements increasing over time. We view these updated results as particularly encouraging for evenamide as an effective treatment for TRS, and continued justification of Newron’s strategy to expand into this schizophrenia patient population.Newron Pharmaceuticals is a clinical stage biopharmaceutical company. Co. is focused on the development of drugs for the treatment of central nervous system disorders and pain. Co.'s pipeline include, Xadago® (safinamide), for the treatment of Parkinson's disease (PD) and PD Levodopa-induced dyskinesia; Sarizotan, for the treatment of Rett syndrome (Orphan drug status); Evenamide (NW-3509), for the treatment of Schizophrenia and Clozapine-treatment-resistant schizophrenia; and Ralfinamide for patients with specific rare pain indications (neuropathic pain).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.